Published in Infect Genet Evol on November 02, 2005
The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J (2007) 4.85
Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol (2009) 3.84
Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother (2006) 3.10
A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J (2009) 2.64
Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. Am J Trop Med Hyg (2012) 1.97
Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J (2008) 1.86
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother (2010) 1.83
Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data. Malar J (2011) 1.76
Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance. PLoS One (2011) 1.73
Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob Agents Chemother (2011) 1.67
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg (2014) 1.51
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother (2010) 1.49
Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. Antimicrob Agents Chemother (2007) 1.44
The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011. PLoS One (2013) 1.29
Selective sweeps and genetic lineages of Plasmodium falciparum drug -resistant alleles in Ghana. J Infect Dis (2011) 1.26
Prevalence of pfmdr1, pfcrt, pfdhfr and pfdhps mutations associated with drug resistance, in Luanda, Angola. Malar J (2008) 1.20
Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum. Malar J (2007) 1.10
Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique. Malar J (2008) 1.09
Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal. Malar J (2012) 1.06
Factors contributing to delay in parasite clearance in uncomplicated falciparum malaria in children. Malar J (2010) 1.04
Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda. J Infect Dis (2009) 1.03
Discordant temporal evolution of Pfcrt and Pfmdr1 genotypes and Plasmodium falciparum in vitro drug susceptibility to 4-aminoquinolines after drug policy change in French Guiana. Antimicrob Agents Chemother (2012) 1.02
Decreased prevalence of Plasmodium falciparum resistance markers to amodiaquine despite its wide scale use as ACT partner drug in Zanzibar. Malar J (2012) 1.00
Monitoring Plasmodium falciparum chloroquine resistance in Yunnan Province, China, 1981-2006. Acta Trop (2008) 0.99
PfMDR1: mechanisms of transport modulation by functional polymorphisms. PLoS One (2011) 0.98
In vitro amodiaquine resistance and its association with mutations in pfcrt and pfmdr1 genes of Plasmodium falciparum isolates from Nigeria. Acta Trop (2011) 0.97
Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study. Malar J (2013) 0.96
Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nat Commun (2016) 0.94
Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations. Pediatr Res (2009) 0.94
Submicroscopic gametocytes and the transmission of antifolate-resistant Plasmodium falciparum in Western Kenya. PLoS One (2009) 0.92
Prevalence of pfmdr1 alleles associated with artemether-lumefantrine tolerance/resistance in Maputo before and after the implementation of artemisinin-based combination therapy. Malar J (2014) 0.92
Evolution of the pfcrt T76 and pfmdr1 Y86 markers and chloroquine susceptibility 8 years after cessation of chloroquine use in Pikine, Senegal. Parasitol Res (2012) 0.92
Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisinin. Antimicrob Agents Chemother (2014) 0.91
Prevalence of molecular markers of drug resistance in an area of seasonal malaria chemoprevention in children in Senegal. Malar J (2013) 0.91
Selection of drug resistance-mediating Plasmodium falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina Faso. Antimicrob Agents Chemother (2014) 0.90
Assessing the cost-benefit effect of a Plasmodium falciparum drug resistance mutation on parasite growth in vitro. Antimicrob Agents Chemother (2012) 0.87
A genome wide association study of Plasmodium falciparum susceptibility to 22 antimalarial drugs in Kenya. PLoS One (2014) 0.87
Seasonal distribution of anti-malarial drug resistance alleles on the island of Sumba, Indonesia. Malar J (2009) 0.86
Analysis of genetic mutations associated with anti-malarial drug resistance in Plasmodium falciparum from the Democratic Republic of East Timor. Malar J (2009) 0.83
Efficacy of amodiaquine in the treatment of uncomplicated falciparum malaria in young children of rural north-western Burkina Faso. Malar J (2008) 0.81
Large-scale surveillance of Plasmodium falciparum crt(K76T) in northern Ghana. Antimicrob Agents Chemother (2007) 0.80
Use of proscribed chloroquine is associated with an increased risk of pfcrt T76 mutation in some parts of Ghana. Malar J (2014) 0.78
Genetics of chloroquine-resistant malaria: a haplotypic view. Mem Inst Oswaldo Cruz (2013) 0.78
Seasonal Malaria Chemoprevention with Sulphadoxine-Pyrimethamine and Amodiaquine Selects Pfdhfr-dhps Quintuple Mutant Genotype in Mali. PLoS One (2016) 0.78
Molecular epidemiology of drug-resistant Plasmodium falciparum in Benguela province, Angola. Malar J (2015) 0.78
Assessment of Markers of Antimalarial Drug Resistance in Plasmodium falciparum Isolates from Pregnant Women in Lagos, Nigeria. PLoS One (2016) 0.76
Prevalence of anti-malarial resistance genes in Dakar, Senegal from 2013 to 2014. Malar J (2016) 0.76
Persistence of chloroquine-resistant haplotypes of Plasmodium falciparum in children with uncomplicated Malaria in Lagos, Nigeria, four years after change of chloroquine as first-line antimalarial medicine. Diagn Pathol (2015) 0.76
Reemergence of chloroquine-sensitive pfcrt K76 Plasmodium falciparum genotype in southeastern Cameroon. Malar J (2017) 0.75
In Vitro and Molecular Surveillance for Antimalarial Drug Resistance in Plasmodium falciparum Parasites in Western Kenya Reveals Sustained Artemisinin Sensitivity and Increased Chloroquine Sensitivity. Antimicrob Agents Chemother (2015) 0.75
Genetic mutations in pfcrt and pfmdr1 at the time of artemisinin combination therapy introduction in South Pacific islands of Vanuatu and Solomon Islands. Malar J (2014) 0.75
Malaria in urban, semi-urban and rural areas of southern of Gabon: comparison of the Pfmdr 1 and Pfcrt genotypes from symptomatic children. Malar J (2016) 0.75
Characterization of Plasmodium falciparum genes associated with drug resistance in Hodh Elgharbi, a malaria hotspot near Malian-Mauritanian border. Malar J (2017) 0.75
Plasmodium falciparum genetic diversity of continental Equatorial Guinea before and after introduction of Artemisinin based Combination Therapy. Antimicrob Agents Chemother (2016) 0.75
Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med (2007) 13.43
In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis (2005) 6.13
Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis (2005) 5.58
Influence of rapid malaria diagnostic tests on treatment and health outcome in fever patients, Zanzibar: a crossover validation study. PLoS Med (2009) 4.55
In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis (2009) 2.80
The benefit of magnetic resonance imaging for patients with posttraumatic radial wrist tenderness. J Hand Surg Am (2012) 2.39
The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int Health (2007) 2.17
Malaria rapid testing by community health workers is effective and safe for targeting malaria treatment: randomised cross-over trial in Tanzania. PLoS One (2011) 1.98
Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infect Genet Evol (2007) 1.84
Diversity of the sarco/endoplasmic reticulum Ca(2+)-ATPase orthologue of Plasmodium falciparum (PfATP6). Infect Genet Evol (2008) 1.80
Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Am J Trop Med Hyg (2003) 1.78
Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance. PLoS One (2011) 1.73
System effectiveness of a targeted free mass distribution of long lasting insecticidal nets in Zanzibar, Tanzania. Malar J (2010) 1.66
Adherence to artesunate-amodiaquine combination therapy for uncomplicated malaria in children in Zanzibar, Tanzania. Trop Med Int Health (2009) 1.65
Plasmodium falciparum accompanied the human expansion out of Africa. Curr Biol (2010) 1.65
Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol (2003) 1.55
Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther (2002) 1.52
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg (2014) 1.51
Anemia and malaria at different altitudes in the western highlands of Kenya. Acta Trop (2004) 1.44
Risks and benefits of targeted malaria treatment based on rapid diagnostic test results. Clin Infect Dis (2010) 1.38
Malaria diagnosis and treatment practices following introduction of rapid diagnostic tests in Kibaha District, Coast Region, Tanzania. Malar J (2013) 1.36
The usefulness of rapid diagnostic tests in the new context of low malaria transmission in Zanzibar. PLoS One (2013) 1.34
Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. Clin Infect Dis (2011) 1.31
Loop-mediated isothermal amplification (LAMP) for point-of-care detection of asymptomatic low-density malaria parasite carriers in Zanzibar. Malar J (2015) 1.30
Expansion of wild type allele rather than back mutation in pfcrt explains the recent recovery of chloroquine sensitivity of Plasmodium falciparum in Malawi. Mol Biochem Parasitol (2004) 1.30
Multiplex PCR-RFLP methods for pfcrt, pfmdr1 and pfdhfr mutations in Plasmodium falciparum. Mol Cell Probes (2006) 1.29
Amodiaquine resistance is not related to rare findings of pfmdr1 gene amplifications in Kenya. Trop Med Int Health (2006) 1.29
Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Antimicrob Agents Chemother (2010) 1.27
Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-finding clinical trial. Clin Infect Dis (2010) 1.27
Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J Infect Dis (2012) 1.26
Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa. J Infect Dis (2009) 1.26
In vitro recombination during PCR of Plasmodium falciparum DNA: a potential pitfall in molecular population genetic analysis. Mol Biochem Parasitol (2002) 1.22
Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives. Malar J (2013) 1.21
Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study. Malar J (2011) 1.20
Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania. Malar J (2013) 1.17
Independent evolution of pyrimethamine resistance in Plasmodium falciparum isolates in Melanesia. Antimicrob Agents Chemother (2007) 1.17
Delayed clearance of Plasmodium falciparum in patients with human immunodeficiency virus co-infection treated with artemisinin. Ethiop Med J (2002) 1.16
Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J Pharmacokinet Pharmacodyn (2007) 1.16
Short report: polymorphisms in the pfcrt and pfmdr1 genes of Plasmodium falciparum and in vitro susceptibility to amodiaquine and desethylamodiaquine. Am J Trop Med Hyg (2007) 1.14
Multiple genotypes of the merozoite surface proteins 1 and 2 in Plasmodium falciparum infections in a hypoendemic area in Iran. Trop Med Int Health (2005) 1.14
Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial. J Infect Dis (2011) 1.13
Drug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America. Malar J (2011) 1.11
Cemented tibial component fixation performs better than cementless fixation: a randomized radiostereometric study comparing porous-coated, hydroxyapatite-coated and cemented tibial components over 5 years. Acta Orthop (2005) 1.11
A qualitative study on caretakers' perceived need of bed-nets after reduced malaria transmission in Zanzibar, Tanzania. BMC Public Health (2012) 1.08
The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria. Trop Med Int Health (2010) 1.07
Role of pfmdr1 mutations on chloroquine resistance in Plasmodium falciparum isolates with pfcrt K76T from Papua New Guinea. Acta Trop (2006) 1.07
Polyclonal Plasmodium falciparum malaria in travelers and selection of antifolate mutations after proguanil prophylaxis. Am J Trop Med Hyg (2002) 1.06
CYP2C8 status of patients with malaria influences selection of Plasmodium falciparum pfmdr1 alleles after amodiaquine-artesunate treatment. J Infect Dis (2012) 1.06
Prevalence of PCR detectable malaria infection among febrile patients with a negative Plasmodium falciparum specific rapid diagnostic test in Zanzibar. Am J Trop Med Hyg (2012) 1.04
Rapid diagnostic tests for molecular surveillance of Plasmodium falciparum malaria -assessment of DNA extraction methods and field applicability. Malar J (2013) 1.04
Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria. Malar J (2011) 1.02
Polymorphism in PfMRP1 (Plasmodium falciparum multidrug resistance protein 1) amino acid 1466 associated with resistance to sulfadoxine-pyrimethamine treatment. Antimicrob Agents Chemother (2009) 1.01
Decreased prevalence of Plasmodium falciparum resistance markers to amodiaquine despite its wide scale use as ACT partner drug in Zanzibar. Malar J (2012) 1.00
The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Med (2015) 0.99
High frequency of recombination-driven allelic diversity and temporal variation of Plasmodium falciparum msp1 in Tanzania. Am J Trop Med Hyg (2007) 0.97
HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya. J Infect Dis (2006) 0.97
Prevalence of resistance associated polymorphisms in Plasmodium falciparum field isolates from southern Pakistan. Malar J (2011) 0.97
In vitro recrudescence of Plasmodium falciparum parasites suppressed to dormant state by atovaquone alone and in combination with proguanil. Trans R Soc Trop Med Hyg (2005) 0.96
Real-time PCR threshold cycle cutoffs help to identify agents causing acute childhood diarrhea in Zanzibar. J Clin Microbiol (2014) 0.95
Allelic dimorphism-associated restriction of recombination in Plasmodium falciparum msp1. Gene (2007) 0.95
Rapid selection of dhfr mutant allele in Plasmodium falciparum isolates after the introduction of sulfadoxine/pyrimethamine in combination with 4-aminoquinolines in Papua New Guinea. Infect Genet Evol (2006) 0.95
Antimalarial exposure delays Plasmodium falciparum intra-erythrocytic cycle and drives drug transporter genes expression. PLoS One (2010) 0.93
Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa. Ther Drug Monit (2008) 0.93
Characteristic age distribution of Plasmodium vivax infections after malaria elimination on Aneityum Island, Vanuatu. Infect Immun (2013) 0.92
Willingness and ability to pay for artemisinin-based combination therapy in rural Tanzania. Malar J (2008) 0.91
Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. Malar J (2015) 0.91
Optimizing the mapping of finger areas in primary somatosensory cortex using functional MRI. Magn Reson Imaging (2008) 0.90
Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur J Clin Pharmacol (2002) 0.90
Pharmacodynamic interactions among atovaquone, proguanil and cycloguanil against Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg (2004) 0.90
Untreated congenital and posttraumatic high dislocation of the hip treated by replacement in adult age: 22 hips in 16 patients followed for 1-8 years. Acta Orthop Scand (2003) 0.89
Advanced radiological work-up as an adjunct to decision in early reconstructive surgery in brachial plexus injuries. J Brachial Plex Peripher Nerve Inj (2010) 0.89
Limited advantage of multiple consecutive samples for genotyping Plasmodium falciparum populations during the first days of treatment. Am J Trop Med Hyg (2005) 0.89
Antipyretic, parasitologic, and immunologic effects of combining sulfadoxine/pyrimethamine with chloroquine or paracetamol for treating uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg (2003) 0.89
The incidence of intrinsic and extrinsic ligament injuries in scaphoid waist fractures. J Hand Surg Am (2010) 0.89
Geographic differentiation of polymorphism in the Plasmodium falciparum malaria vaccine candidate gene SERA5. Vaccine (2012) 0.88
Sentinel network for monitoring in vitro susceptibility of Plasmodium falciparum to antimalarial drugs in Colombia: a proof of concept. Mem Inst Oswaldo Cruz (2011) 0.87
Assessing the cost-benefit effect of a Plasmodium falciparum drug resistance mutation on parasite growth in vitro. Antimicrob Agents Chemother (2012) 0.87
Endophilic Anopheles mosquitoes in Guinea Bissau, west Africa, in relation to human housing conditions. J Med Entomol (2004) 0.86
Epidemiology of malaria in a village in the Rufiji River Delta, Tanzania: declining transmission over 25 years revealed by different parasitological metrics. Malar J (2014) 0.84
Sensory feedback from a prosthetic hand based on air-mediated pressure from the hand to the forearm skin. J Rehabil Med (2012) 0.83
Subjective outcome related to donor site morbidity after sural nerve graft harvesting: a survey in 41 patients. BMC Surg (2013) 0.83
Malaria dispersal among islands: human mediated Plasmodium falciparum gene flow in Vanuatu, Melanesia. Acta Trop (2004) 0.83
Principles of brain plasticity in improving sensorimotor function of the knee and leg in healthy subjects: a double-blind randomized exploratory trial. BMC Musculoskelet Disord (2009) 0.81
Improved sensibility of the foot after temporary cutaneous anesthesia of the lower leg. Neuroreport (2009) 0.81
High effective coverage of vector control interventions in children after achieving low malaria transmission in Zanzibar, Tanzania. Malar J (2013) 0.81
Carriers, channels and chloroquine efficacy in Guinea-Bissau. Trends Parasitol (2007) 0.81
Transfer of tactile input from an artificial hand to the forearm: experiments in amputees and able-bodied volunteers. Disabil Rehabil Assist Technol (2012) 0.81
Invasive Mycobacterium marinum infection of the hand. J Plast Surg Hand Surg (2013) 0.81